Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 743-749

  Croze, E D ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERFERON BETA SERINE; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RNA TRANSLATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME; VIRUS INFECTION;

GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957372656     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0022     Document Type: Review

References (77)

1. Achiron A, Gurevich M, Friedman N., Kaminski N, Mandel M. 2004. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol '55:410-417.
2. Agrawal SM, Yong WW 2007. Immunopathogenesis of MS. Int Rev Neurobiol 79:99-126.
3. Arnason BGW, Dayal A, Qu Z.X., Jensen M., Genç K, Reder AT. 1996. Mechanisms of action of interferon beta in multiple sclerosis. Semin Immunopathol '18:125-148.
4. Axtell RC, de Jong BA, Boniface K, van der Voort L, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. Thelper type I and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med '16:406-412.
5. Baranzini SE, Mousavi P, Rio J., Caillier SJ, Stillman A, Villoslada P, Wyatt M.M., Comabella M., Greller LD, Somogyi R, Montalban X, Oksenberg JR. 2005. Transcription-based prediction of response to IFN-β using supervised computational methods. PLoS Biol 3:E2.
6. Bauch A, Superti-Furga G. 2006. Charting protein complexes, signaling pathways, and networks in the immune system. Immunol Rev '210:187-207.
7. Bild A, Febbo PG 2005. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc Natl Acad Sci U S A '102:15278-15279.
8. Brazhnik P, de la Fuente A, Mendes P. 2002. Gene networks: how to put the function in genomics Trends Biotech 20: 467-472.
9. Byskosh PV, Reder AT 1996. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler '1:262-269.
10. Calabresi PA, Tranquill R, Dambrosia J.M., Stone L., Maloni H, Bash CN, Frank J, McFarland HF 1997. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. J Neuroimmunol '41:669-674.
11. Calvan ES, Xiao W, Richards D.R., Felciano RM, Baker HV, Cho RJ, Chen R.O., Brownstein HB, Cobb JP, Tschoeke SK, Miller-Graziano LC, Moldawe L, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF. 2005. A network-based analysis of systemic inflammation in humans. Nature '437:1032-1037.
12. Chatzimanolis N, Kraus J, Bauer R., Engelhart B, Bregenzer T, Kuehne B.S., Tofighi J., Laske C, Stolz F, Blaes F, Voigt K, Traupe H, Kaps M. Oschmann. 2004. CD45RA+ ICAM3+ lymphocytes in interferon beta-1b treated and untreated patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand '110:377-385.
13. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. 2009. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain '132:3353-3365.
14. Corvol J-C, Pelletier D., Henry RG, Cailler SJ, Wang J, Pappas D., Casazza S, Okuda DT, Hauser SL, Oksenberg JR, Baranzini SE. 2008. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. PNAS '105:11830-11844.
15. Croze E, Beekman J, Knappertz, V, Sanbrink R., Pohl C, Paz P, Lindberg R., Kappos L, Reischl J. 2009a. Betaseron increases expression of metallothioneins in relapsing-remitting multiple sclerosis patients suggesting a role for betaseron in neuro-protection. Mult Scler 15:S138.
16. Croze E, Velichko S, Tran T., Yamaguchi KD, Salamon H, Reder AT, Knappertz V, Paz P. 2009b. Betaseron induces a novel alternative start transcript in cells obtained from relapsing-remitting multiple sclerosis patients and human brain that is associated with control of oxidative resistance. Mult Scler 15:S138.
17. Cunningham S, Graham C, Hutchinson M., Droogan A, O'Rourke K, Patterson C, McDonnell G., Hawkins S, Vandenbroeck K. 2005. Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther '78:635-646.
18. Der S, Zhou A, Williams B., Silverman RH 1998. Identification of genes differentially regulated by interferons a, b, or g using oligonucleotide arrays. Proc Natl Acad Sci USA '95:15623-15628.
19. Dhib-Jalbut S., Marks S. 2010. Interferon-β mechanisms of action in multiple sclerosis. Neurology '74:S17-S24.
20. Fernald GH, Knott S, Pachner A., Caillier SJ, Narayan K, Ok-senberg JR, Mousavi P, Baranzini SE 2007. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol '178:5076-5085.
21. Floris S, Ruuls SR, Wierinck A, van der Pol SM, Dopp E, van der Meide PH, Dijkstra CD, De Vries HE. 2002. Interferon-β directly influences monocyte inflitration into the central nervous system. J Neuroimmunol '127:69-79.
22. Fujinami RS, von Herrath M, Christen U, Whitton JL 2006. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Micro Rev '19: 80-94.
23. Gniadek P, Oktas O, Wandlinger K-P, Bellmann-Strobi J, Wengert O., Weber A, von Wussow P, Obert H-J, Zipp F. 2003. Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol '137:187-196.
24. Goertsches RH, Hecker M, Zerrl UK 2008. Monitoring of multiple sclerosis immunotherapy from single candidates to bio-marker networks. J Neurol '255:48-57.
25. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest '118:1680-1690.
26. Hafler DA, Slavik J, Anderson D.E., O'Connor K, De Jager P, Baecher-Allan C. Multiple Sclerosis. 2005. Immunol Rev '204: 208-231.
27. Hartrich L, Weinstock-Guttman B, Hall D., Badgett D, Baier M, Patrick K., Feichter J, Hong J, Ramanathan M. 2003. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. J Neuroimmunol '139:84-92.
28. Hilpert J, Beekman JM, Schwenke S, Kowal K., Bauer D, Lampe J, Sandbrink R., Heubach JF, Stürzebecher S, Reischl J. 2008. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol '199:115-125.
29. Hong J, Zang Y, Hutton G., Rivera V, Zhang, J. 2004. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol '152:126-139.
30. Hood L, Heath JR, Phelps M.E., Lin B. 2004. Systems biology and new technologies enable predictive and preventative medicine. Science '306:640-643.
31. Hoops S, Sahle S, Gauges R., Lee C, Pahle J, Simus N., Singhal M, Xu L, Nendes P, Kummer U. 2006. COPASI a complex pathway simulator. Bioinformatics '22:3067-3074.
32. Iglesias AH, Camelo S, Hwang D., Villanueva R, Stephanopoulos G, Dangond F. 2004. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol '150:163-177.
33. Keegan BM, Noseworthy JH 2002. Multiple sclerosis. Ann Rev Med '53:285-302.
34. Ketlinskiy SA, Kalinina NM 2008. Cytokines in demyelinating diseases. In: Phelps C, Korneva E, eds. Cytokines and the brain. Atlanta, GA, USA: Elsevier B.V., pp 455-483.
35. Koike F, Satoh J, Miyake S., Yamamoto T, Kawai M, Kikuchi S., Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T. 2003. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis. J Neuroimmunol '139:109-118.
36. Kurzke JF. 1983. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452.
37. Lallemand C, Meritet JF, Erickson R, Grossberg S.E., Roullet E., Lyon-Caen O, Lebon P, Tovey MG 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res '28:393-404.
38. Lee NH. 2005. Genomic approaches for reconstructing gene networks. Pharmacogenomics '6:245-258.
39. Lengyel P. 1982. Biochemistry of interferon and their actions. Ann Rev Biochem '51:251-282.
40. Leppert D, Waubant E. 1996. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol '40:846-852.
41. Linkov F, Ferris RL, Yurkovetsky Z, Marrangoni A., Veliko-khatnaya L, Gooding W, Nolan B., Winans M, Siegel ER, Lokshin A, Stack BC. 2008. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl '10:1575-1585.
42. Martin-Saavedra F.M., Gonzalez-Garcia C, Bravo B., Ballester S. 2008. β-interferon restricts the inflammatory potential of CD4+cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol '45:4008-4019.
43. McDonald WI, Compston A, Edan G., Goodin D, Hartung HP, Lublin F.D., McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol '50:121-127.
44. Muraro PA, Liberati L, Bonanni L., Pantaline CM, Caporale C, Iarlori G, DeLuca D., Farina A, Lugaresi D, Gambi D. 2004. Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J Neuroimmunol '150: 123-131.
45. O'Sullivan L.A., Liongue C, Lewis R.S., Stephenson SE, Ward AC 2007. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol '44:2497-2506.
46. Owens T, Bechmann I, Engelhardt B. 2008. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol '12:1113-1121.
47. Pachner AR, Bertolotto A, Deisenhammer F. 2003. Measurement of MxA mRNA or protein as a biomarker of IFN beta bioactivity:detection of antibody-mediated decreased bioactivity (ADA). Neurology 61:S24-S26.
48. Penkowa M, Hidalgo J. 2003. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimential autoimmune encephalomyelitis. J Neurosci Res '72:574-586.
49. Pesu M, Laurence A, Kishore N., Zwillich SH, Chan G, O'Shea JJ. 2008. Therapeutic targeting of janus kinases. Immunol Rev '223:132-142.
50. Rani MR, Xu Y, Lee J.C., Shrock J., Josyula A, Schlaak J, Chakraborthy S., Ja N, Ransohoff RM, Rudick RA. 2009. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci '1182:58-68.
51. Reder AT, Velichko S, Yamaguchi K.D., Hamamcioglu K., Ku K, Beekman J, Wagner T.C., Perez, HD, Salamon H, Croze E. 2008. IFN-β1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res '28:317-331.
52. Rio J, Comabella M, Montalban X. 2009. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol '5:553-560.
53. Robinson WH, Utz P, Steinman L. 2003. Genomic and proteomic analysis of multiple sclerosis. Curr Opin Immunol '15:660-667. (Pubitemid 37434074)
54. Russell-Harde D., Wagner TC, Perez H.D., Croze E. 1999. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun '255:539-544.
55. Ruan Y, Le Bar P, Ng HH, Liu ET 2004. Interrogating the transcriptome. Trends Biotech '20:23-30.
56. Satoh J, Nanri Y, Tabunoki H., Yamamura T. 2006. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN-β-response genes in peripheral blood lymphocytes in vitro: an implication for IFN-β-related adverse effects in multiple sclerosis. BMC Neurol '6:18-29.
57. Serrano-Fernandez P., Moller S, Goertsches R., Fiedler H, Koczan D, Thiesen H.J., Zettl, UK. 2010. Time course transcriptomic of IFN-β1b drug therapy in multiple sclerosis. Autoimmunity '43:172-178.
58. Sharief MK, Semra YK 2002. Down-regulation of survivin expression in T-lymphocytes after interferon-β1a treatment in patients with multiple sclerosis. Arch Neurol '59:1115-1121.
59. Stark GR, Kerr IM, Williams B.R., Silverman RH, Schreiber RD 1998. How cells respond to interferons. Annu Rev Biochem '67:227-264.
60. Stürzebecher S., Maibauer R, Heuner A., Beckmann K, Aufdem-brinke B. 1999. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res '19:1257-1264.
61. Stürzebecher S., Wandinger KP, Rosenwald A, Sathyamoorthy M., Tzou A, Mattar P, Frank J.A., Staudt L., Martin R, McFarland HF. 2003. Expression profiling identifies responder and non-responder phenotypes to interferon beta in multiple sclerosis. Brain '126:1419-1429.
62. Stüve O., Chabot S, Jung S.S., Williams G., Yong VW 1997. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 80:38-46.
63. Subramanian A, Tamayo P, Mootha V.K., Mukherjee S., Ebert BL, Gillette MA, Paulovich A, Pomeroy S.L., Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A '102:15545-15550.
64. The IFN beta Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology '43:655-661.
65. Trojano M, Avolio C. 1999. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology 53:52-57.
66. Tzartos JS, Friese MA, Craner M.J., Palace J., Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol '172:146-155.
67. Vallittu AM, Saraste M, Airas L. 2007. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res '29:763-766.
68. Van Baarsen L.G., Vosslamber S, Tijssen M., Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. 2008. Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS 3:E1927.
69. Vosslamber S, van Baarsen L, Verweij CL 2009. Pharmacoge-nomics of IFN-β in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics '10:97-108.
70. Wandinger KP, Stürzebecher CS, Bielekova B., Detore G, Rosenwald A, Staudt L.M., McFarland HF, Martin R. 2001. Complex immunomodulatory effects of interferon beta in multiple sclerosis including the upregulation of T helper 1-associated marker genes. Ann Neurol '59:349-357.
71. Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet '10:57-63.
72. Waubant E, Gee L, Bacchetti P., Sloan R, Cotleur A, Rudick R., Goodkin D. 2001. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 112:139-145.
73. Weiner HL. 2009. The challenge of multiple sclerosis: how do we cure a chronic heterogenous disease? Ann Neurol 65:239-248.
74. Weinstock-Guttman B., Badgett D, Patrick K., Hartrich L, Santos R, Hall D., Baier M, Feicher J, Ramanathan M. 2003. Genomic effects of IFN-β in multiple sclerosis patients. J Immunol '171:2694-2702.
75. Weinstock-Guttman B., Ransohoff RM, Kinkel P, Rudick RA 1995. The interferons: biologic effects, mechanism of action, and use in multiple sclerosis. Ann Neurol '37:7-15.
76. Wills RJ. 1990. Clinical pharmacokinetics of interferons. Clin Pharmacokinet '19:390-399.
77. Yamaguchi KD, Ruderman DL, Croze E, Wagner T.C., Velichko S., Reder AT, Salamon H. 2008. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neurol '195:116-120.